Skip to main content
SpringerLink
Log in

Efficacy of the calcium antagonist isradipine in angina pectoris

  • Clinical Studies
  • Focus On Calcium Modulation
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Thirty-six patients with chronic, stable angina pectoris were studied during 2-week treatment periods in which they received, in a randomized double-blind, crossover study, a new calcium entry blocking agent, isradipine, 7.5 mg three times daily or placebo. Antianginal efficacy was determined by treadmill exercise testing carried out 3 and 9 hours after drug administration on the final day of each treatment period. During placebo therapy, treadmill exercise time to the onset of angina (P1) and to the development of moderate angina (P2) was similar at 3 and 9 hours and similar to the placebo run-in period. During isradipine therapy, treadmill exercise time 3 hours after dosing was greater than with placebo therapy (P1 312±23.0 vs. 267±19.5 seconds,p<0.001; P2 410±20.2 vs. 355±18.8 seconds,p<0.002). Nine hours after drug administration, the results of exercise testing were similar to placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pepine CJ, Feldman RL, Hill JA, et al. Clinical outcome after treatment of rest angina with calcium blockers: Comparative experience during the initial year of therapy with diltiazem, nifedipine and verapamil.Am Heart J 1983; 106:1341–1346.

    Article  PubMed  Google Scholar 

  2. Subramanian VB, Bowles MJ, Khurmi NS, et al. Randomized double blind comparison of verapamil and nifedipine in chronic stable angina.Am J Cardiol 1982; 50:696–703.

    Article  PubMed  Google Scholar 

  3. Waters DD, Theroux P, Szlachcic J, et al. Provocative testing with ergonovine to assess the efficacy of treatment with nifedipine, diltiazem and verapamil in variant angina.Am J Cardiol 1981; 48:123–130.

    PubMed  Google Scholar 

  4. Gertenblith G, Ouyang P, Achuff SC. Nifedipine in unstable angina: A double blind randomized trial.N Engl J Med 1982; 306:885–889.

    PubMed  Google Scholar 

  5. Agabiti-Rosei E, Muiesan ML, Romanelli G. Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine.J Am Coll Cardiol 1986; 7:916–924.

    PubMed  Google Scholar 

  6. Klein W, Brandt D, Vrecko K, et al. Role of calcium antagonists in the treatment of essential hypertension.Circ Res 1983; 52(2 pt 2):I174–181.

    PubMed  Google Scholar 

  7. Erne P, Bolli P, Bertel O. Factors influencing the hypotensive effects of calcium antagonists.Hypertension 1983; 5(4 pt 2):II-97–II-102.

    Google Scholar 

  8. Strauer BE, Mahmoud A, Bayer F, et al. Reversal of left ventricular hypertrophy and improvement of cardiac function in man by nifedipine.Eur Heart J 1984; 5(Suppl F):53–60.

    Google Scholar 

  9. Low RI, Takeda P, Mason DT, et al. The effects of calcium channel blocking agents on cardiovascular function.Am J Cardiol 1982; 49:547–553.

    PubMed  Google Scholar 

  10. Cohn JN. Calcium antagonists and left ventricular function: Effects of nitrendipine in congestive heart failure.Am J Cardiol 1986; 58:27D-30D.

    Article  PubMed  Google Scholar 

  11. Hof RP, Hof A, Scholtysik G, et al. Effects of the new calcium antagonist PN200-110 on the myocardium and the regional peripheral circulation in anesthetized cats and dogs.J Cardiovasc Pharmacol 1984; 6:407–416.

    PubMed  Google Scholar 

  12. Wada Y, Satoh K, Taira N. A study on the separation of the coronary vasodilator from cardiac effects of PN200-110, a new dihydropyridine calcium antagonist, in the dog heart.J Cardiovasc Pharmacol 1985; 7:190–196.

    PubMed  Google Scholar 

  13. Muller-Schweinitzer E, Neumann P. In vitro effects of the calcium antagonist PN200-110, nifedipine, the nimodipine on human and canine cerebral arteries.J Cereb Blood Flow Metab 1983; 3:354–361.

    PubMed  Google Scholar 

  14. Nelson EB, Pool JL, Taylor AA, Antihypertensive activity of isradipine in humans; a new dihydropyridine calcium channel antagonist.Clin Pharmacol Ther 1986; 40:694–697.

    PubMed  Google Scholar 

  15. Handler CE, Sowton E. Safety, tolerability and efficacy of isradipine, a new calcium antagonist in patients with angina and coronary heart disease.Eur J Clin Pharmacol 1984; 27:415–417.

    Article  PubMed  Google Scholar 

  16. Feldman RL, Hill JA, Conti JB, et al. Analysis of coronary responses to nifedipine alone and in combination with intracoronary nitroglycerin in patients with coronary artery disease.Am Heart J 1983; 105:651–658.

    Article  PubMed  Google Scholar 

  17. Bassan M, Weiler-Ravall D, Shalev O. The additive antianginal action of oral nifedipine in patients receiving propranolol: Magnitude and duration of effect.Circulation 1982; 66:710–716.

    PubMed  Google Scholar 

  18. Leon MB, Rosing DR, Bonow RD, et al. Combination therapy with calcium-channel blocker and beta-blockers for chronic stable angina pectoris.Am J Cardiol 1985; 55:69B-80B.

    Article  PubMed  Google Scholar 

  19. White HD, Polak JF, Wynne J, et al. Addition of nifedipine to maximal nitrate and beta-adrenoreceptor blocker therapy in coronary artery disease.Am J Cardiol 1985; 55:1303–1307.

    Article  PubMed  Google Scholar 

  20. Halperin AK, Gross KM, Rogers JF, et al. Verapamil and propranolol in essential hypertension.Clin Pharmacol Ther 1984; 36:750–758.

    PubMed  Google Scholar 

  21. Hossack KF, Pool PE, Steele P. Efficacy of diltiazem in angina on effort: A multicentre trial.Am J Cardiol 1982; 49:567–572.

    PubMed  Google Scholar 

  22. Ferlinz J. Nifedipine in myocardial ischemia, systemic hypertension and other cardiovascular disorders.Ann Intern Med 1986; 105:714–729.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen's University, Kingston, Ontario

    John O. Parker MD, Marc Enjalbert & Victoria Bernstein

  2. University of British Columbia, Vancouver, B.C.

    John O. Parker MD, Marc Enjalbert & Victoria Bernstein

  3. Sandoz Canada, Inc., Dorval, Quebec, Canada

    John O. Parker MD, Marc Enjalbert & Victoria Bernstein

Authors
  1. John O. Parker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Enjalbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Victoria Bernstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parker, J.O., Enjalbert, M. & Bernstein, V. Efficacy of the calcium antagonist isradipine in angina pectoris. Cardiovasc Drug Ther 1, 661–664 (1988). https://doi.org/10.1007/BF02125752

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02125752

Key words

Search

Navigation